Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations
Open accessThe DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Abstract
Proinflammatory cytokines are potent mediators of numerous biological processes and are tightly regulated in the body. Chronic uncontrolled levels of such cytokines can initiate and derive many pathologies, including incidences of autoimmunity and cancer. Therefore, therapies that regulate the activity of inflammatory cytokines, either by supplementation of anti-inflammatory recombinant cytokines or by neutralizing them by using blocking antibodies, have been extensively used over the past decades. Over the past few years, new innovative biological agents for blocking and regulating cytokine activities have emerged. Here, we review some of the most recent approaches of cytokine targeting, focusing on anti-TNF antibodies or recombinant TNF decoy receptor, recombinant IL-1 receptor antagonist (IL-1Ra) and anti-IL-1 antibodies, anti-IL-6 receptor antibodies, and TH17 targeting antibodies. We discuss their effects as biologic drugs, as evaluated in numerous clinical trials, and highlight their therapeutic potential as well as emphasize their inherent limitations and clinical risks. We suggest that while systemic blocking of proinflammatory cytokines using biological agents can ameliorate disease pathogenesis and progression, it may also abrogate the hosts defense against infections. Moreover, we outline the rational need to develop new therapies, which block inflammatory cytokines only at sites of inflammation, while enabling their function systemically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These AEs are frequently observed in biologics targeting immune checkpoints, or cytokines (Rider et al., 2016; Postow et al., 2018).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Rider et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · cited 1×
“Previously termed “IL-23-derived autoreactive CD4 T cells,” TH17 cells were named after IL-17 cytokine (which they produce) and are correlated with autoimmunity disorders including RA, lupus, colitis, and EAE [125, 126].”
BackgroundAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Increased expression of interleukin 17 in inflammatory bowel disease
Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., Bamba, T., & Fujiyama, Y. (2003) · Gut · doi:10.1136/gut.52.1.65 · Cited by 1,713
Signal transduction by tumor necrosis factor and its relatives
Baud, V., & Karin, M. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02064-5 · Cited by 1,655
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Tumor Necrosis Factor-α Signaling in Macrophages
Parameswaran, N., & Patial, S. (2010) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v20.i2.10 · Cited by 1,437
Angiogenesis and Inflammation in Peritoneal Dialysis: The Role of Adipocytes
Shi, J., Yu, M., & Sheng, M. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000476017 · Cited by 1,403
Cited by
Cytokines: From Clinical Significance to Quantification
Liu, C., Chu, D., Kalantar‐Zadeh, K., George, J., Young, H. A., & Liu, G. (2021) · Advanced Science · doi:10.1002/advs.202004433 · Cited by 940
Han, X., Xu, T., Fang, Q., Zhang, H., Yue, L., Hu, G., & Sun, L. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102010 · Cited by 544
Han, X., Sun, S., Sun, Y., Song, Q., Zhu, J., Song, N., Chen, M., Sun, T., Xia, M., Ding, J., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1596481 · Cited by 408
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Emerging principles of cytokine pharmacology and therapeutics
Saxton, R. A., Glassman, C. R., & Garcia, K. C. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00557-6 · Cited by 215
Advances in Receptor‐Mediated, Tumor‐Targeted Drug Delivery
Large, D. E., Soucy, J. R., Hebert, J., & Auguste, D. T. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800091 · Cited by 190
Tamura, Y., Phan, C., Tu, L., Le Hiress, M., Thuillet, R., Jutant, E.-M., Fadel, E., Savale, L., Huertas, A., Humbert, M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96462 · Cited by 176
Musolino, C., Allegra, A., Innao, V., Allegra, A. G., Pioggia, G., & Gangemi, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/1852517 · Cited by 168
Microstructure, pathophysiology, and potential therapeutics of COVID‐19: A comprehensive review
Singh, S. P., Pritam, M., Pandey, B., & Yadav, T. P. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26254 · Cited by 166
Neuraxial Cytokines in Pain States
Gonçalves dos Santos, G., Delay, L., Yaksh, T. L., & Corr, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03061 · Cited by 162
Mechanism and Prevention of Titanium Particle-Induced Inflammation and Osteolysis
Eger, M., Hiram‐Bab, S., Liron, T., Sterer, N., Carmi, Y., Kohavi, D., & Gabet, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02963 · Cited by 160
Self-citationSenescence and the tumor-immune landscape: Implications for cancer immunotherapy
Chibaya, L., Snyder, J. T., & Ruscetti, M. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.005 · Cited by 161
Arnold, D. D., Yalamanoglu, A., & Boyman, O. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888392 · Cited by 156
Mast Cells as Drivers of Disease and Therapeutic Targets
Siebenhaar, F., Redegeld, F. A., Bischoff, S. C., Gibbs, B. F., & Maurer, M. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.10.005 · Cited by 131
Litmanovich, A., Khazim, K., & Cohen, I. (2018) · Oncology and Therapy · doi:10.1007/s40487-018-0089-z · Cited by 116
Self-citationNordin, U. U. M., Ahmad, N., Salim, N., & Yusof, N. S. M. (2021) · RSC Advances · doi:10.1039/d1ra06087b · Cited by 127
Constitutive Inflammatory Cytokine Storm: A Major Threat to Human Health
Gupta, K. K., Khan, M. A., & Singh, S. K. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2019.0085 · Cited by 115
Günther, S., Fagone, P., Jalce, G., Atanasov, A. G., Guignabert, C., & Nicoletti, F. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.003 · Cited by 111
Monoterpenes modulating cytokines - A review
Quintans, J. D. S. S., Saravanan, S., Heimfarth, L., Araújo, A. A. D. S., Almeida, J. R. G. D. S., Picot, L., & Quintans‐Júnior, L. J. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.10.058 · Cited by 125
Polymeric particle-based therapies for acute inflammatory diseases
Brannon, E. R., Guevara, M. V., Pacifici, N. J., Lee, J. K., Lewis, J. S., & Eniola‐Adefeso, O. (2022) · Nature Reviews Materials · doi:10.1038/s41578-022-00458-5 · Cited by 107
Kwon, M., Lee, J., Park, S., Kwon, O.-H., Seo, J., & Roh, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239283 · Cited by 107
Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment
Reale, M., Costantini, E., & Greig, N. H. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.536257 · Cited by 96
Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies
Mallick, R., Basak, S., Chowdhury, P., Bhowmik, P., Das, R. K., Banerjee, A., Paul, S., Pathak, S., & Duttaroy, A. K. (2025) · Pharmaceuticals · doi:10.3390/ph18010104 · Cited by 119
Anti-Inflammatory Therapy for Atherosclerosis: Focusing on Cytokines
Poznyak, A. V., Bharadwaj, D., Prasad, G., Grechko, A. V., Sazonova, M. A., & Orekhov, A. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137061 · Cited by 102
Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer
Marković, I., & Savvides, S. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01557 · Cited by 86
Local drug delivery systems for inflammatory diseases: Status quo, challenges, and opportunities
Chen, Y.-C., Gad, S. F., Chobisa, D., Li, Y., & Yeo, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.025 · Cited by 85
Targets of immunomodulation in bacterial endophthalmitis
Miller, F. C., Coburn, P. S., Mursalin, H., LaGrow, A. L., Livingston, E. T., & Callegan, M. C. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.05.004 · Cited by 74
Long Non-Coding RNAs as Mediators of Tumor Microenvironment and Liver Cancer Cell Communication
Lin, Y.-H., Wu, M., Yeh, C., & Lin, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123742 · Cited by 77
Endothelial cells, neutrophils and platelets: getting to the bottom of an inflammatory triangle
Dehghani, T., & Panitch, A. (2020) · Open Biology · doi:10.1098/rsob.200161 · Cited by 81
Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1β release
Starobova, H., Monteleone, M. M., Adolphe, C., Batoon, L., Sandrock, C. J., Tay, B., Deuis, J. R., Smith, A. V., Mueller, A., Nadar, E. I., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201452 · Cited by 81
Autoimmune rheumatic diseases: One or many diseases?
Moutsopoulos, H. Μ. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100129 · Cited by 87
Targeting the NLRP3 Inflammasome in Glaucoma
Coyle, S., Khan, M. N., Chemaly, M., Callaghan, B., Doyle, C., Willoughby, C. E., Atkinson, S. D., Gregory-Ksander, M. S., & McGilligan, V. (2021) · Biomolecules · doi:10.3390/biom11081239 · Cited by 73
Cell Membrane‐Coated Nanoparticles: A New Frontier in Immunomodulation
Desai, N., Tambe, V., Pofali, P., & Vora, L. K. (2024) · Advanced NanoBiomed Research · doi:10.1002/anbr.202400012 · Cited by 81
Rheumatoid arthritis: the old issue, the new therapeutic approach
Babaahmadi, M., Tayebi, B., Gholipour, N. M., Kamardi, M. T., Heidari, S., Baharvand, H., Eslaminejad, M. B., Hajizadeh‐Saffar, E., & Hassani, S. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03473-7 · Cited by 90
Yang, J., Chaudhry, M. T., Yao, J., Wang, S. N., Zhou, B., Wang, M., Han, C., You, Y., & Li, Y. (2017) · Journal of Animal Physiology and Animal Nutrition · doi:10.1111/jpn.12778 · Cited by 68
Garza, G. R. C., Elizondo‐Luévano, J. H., Bazaldúa-Rodríguez, A. F., Chávez-Montes, A., Pérez-Hernández, R. A., Delgado, A. J. M., Villarreal, S. M. L., Rodríguez‐Rodríguez, J., Sánchez‐Casas, R., Castillo-Velázquez, U., et al. (2021) · Plants · doi:10.3390/plants10091908 · Cited by 70
Markovics, A., Rosenthal, K. S., Mikecz, K., Carambula, R. E., Ciemielewski, J. C., & Zimmerman, D. H. (2021) · Biomedicines · doi:10.3390/biomedicines10010044 · Cited by 67
Arora, S., Cooper, P. R., Friedlander, L. T., Rizwan, S. B., Seo, B., Rich, A. M., & Hussaini, H. M. (2021) · International Endodontic Journal · doi:10.1111/iej.13524 · Cited by 65
Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation
Roy, T., Banang‐Mbeumi, S., Boateng, S. T., Ruiz, E. M., Chamcheu, R. N., Kang, L., King, J. A. C., Walker, A. L., Nagalo, B. M., Kousoulas, K. G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1075804 · Cited by 67
Pezhman, L., Tahrani, A. A., & Chimen, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.624184 · Cited by 69
Yadav, K., Singh, D., & Singh, M. R. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.07.021 · Cited by 58
Therapeutic potential of sulfur-containing natural products in inflammatory diseases
Cao, X., Cao, L., Zhang, W., Lu, R., Bian, J., & Nie, X. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107687 · Cited by 55
Youn, H. S., Kim, J., Lee, J. S., Yoon, Y. Y., Choi, S. J., Lee, J. Y., Kim, W., & Hwang, K. W. (2021) · Infection and Immunity · doi:10.1128/iai.00615-20 · Cited by 57
Treatments for Pulmonary Ricin Intoxication: Current Aspects and Future Prospects
Gal, Y., Mazor, O., Falach, R., Sapoznikov, A., Kronman, C., & Sabo, T. (2017) · Toxins · doi:10.3390/toxins9100311 · Cited by 58
Immunological Responses to Envenomation
Ryan, R. Y. M., Seymour, J., Loukas, A., Lopez, J. A., Ikonomopoulou, M. P., & Miles, J. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661082 · Cited by 49
“Cytokines and their respective receptors represent important immunotherapeutic targets for numerous conditions (96).”
BackgroundNicolescu, A. C., Ionescu, M., Constantin, M. M., Ancuta, I., Ionescu, S. O., Niculeț, E., Tatu, A. L., Zirpel, H., & Thaçi, D. (2022) · Life · doi:10.3390/life12122050 · Cited by 48
JAK-STAT Signaling in Autoimmunity and Cancer
Parveen, S., Fatma, M., Mir, S. S., Dermime, S., & Shahab Uddin, M. S. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s485670 · Cited by 65
The Role, Involvement and Function(s) of Interleukin-35 and Interleukin-37 in Disease Pathogenesis
Bello, R. O., Chin, V. K., Isnadi, M. F. A. R., Majid, R. A., Abdullah, M. A., Lee, T. Y., Zakaria, Z. A., Hussain, M. K., & Basir, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041149 · Cited by 53
Sacco, R., Shah, S., Leeson, R., Moraschini, V., Mourão, C. F., Akintola, O., & Lalli, A. (2019) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2019.09.023 · Cited by 47
Cuccarese, M. F., Earnshaw, B. A., Heiser, K., Fogelson, B., Davis, C. T., McLean, P. F., Gordon, H. B., Skelly, K.-R., Weathersby, F. L., Rodic, V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.02.233064 · Cited by 47
Ferulic Acid Supplementation for Management of Depression in Epilepsy
Singh, T., Kaur, T., & Goel, R. K. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2325-6 · Cited by 48
Discovering in vivo cytokine-eQTL interactions from a lupus clinical trial
Davenport, E. E., Amariuta, T., Gutierrez-Arcelus, M., Slowikowski, K., Westra, H.-J., Luo, Y., Shen, C., Rao, D. A., Zhang, Y., Pearson, S., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1560-8 · Cited by 46
Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases
Vong, C. T., Tseng, H. H. L., Yao, P., Yu, H., Wang, S., Zhong, Z., & Wang, Y. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.018 · Cited by 51
Antiinflammatory Potential of Medicinal Plants: A Source for Therapeutic Secondary Metabolites
Bernstein, N., Akram, M., Daniyal, M., Koltai, H., Fridlender, M., & Gorelick, J. (2018) · Advances in agronomy · doi:10.1016/bs.agron.2018.02.003 · Cited by 55
Current and novel therapeutic targets in the treatment of rheumatoid arthritis
George, G., Shyni, G. L., & Raghu, K. G. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00757-9 · Cited by 48
Breaking Down Osteoarthritis: Exploring Inflammatory and Mechanical Signaling Pathways
Batarfi, W. A., Yunus, M. H. M., Hamid, A. A., Maarof, M., & Rani, R. A. (2025) · Life · doi:10.3390/life15081238 · Cited by 59
Mansoori, M. N., Raghuvanshi, A., Shukla, P., Awasthi, P., Trivedi, R., Goel, A., & Singh, D. R. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106299 · Cited by 46
Giustarini, G., Pavesi, A., & Adriani, G. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.689245 · Cited by 48
Wells, K., Liu, T., Zhu, L., & Yang, L. P. H. (2024) · Nanoscale · doi:10.1039/d4nr01780c · Cited by 46
Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost
Tabaa, M. M. E., & Tabaa, M. M. E. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114057 · Cited by 44
A review of brain insulin signaling in mood disorders: From biomarker to clinical target
Nguyen, T. T. L., Chan, L. C., Borreggine, K. L., Kale, R. P., Hu, C., & Tye, S. J. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.05.014 · Cited by 45
Xu, S., Peng, H., Wang, N., & Meng, Z. (2018) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v17i2.12 · Cited by 36
NLRP3 Sensing of Diverse Inflammatory Stimuli Requires Distinct Structural Features
Rahman, T., Nagar, A., Duffy, E. B., Okuda, K., Silverman, N. S., & Harton, J. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01828 · Cited by 37
Therapeutic potential of the FPR2/ALX agonist AT-01-KG in the resolution of articular inflammation
Galvão, I., Melo, E. M., de Oliveira, V. L. S., Vago, J. P., Queiroz‐Junior, C. M., de Gaetano, M., Brennan, E. P., Gahan, K., Guiry, P. J., Godson, C., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105445 · Cited by 34
Learning from the nexus of autoimmunity and cancer
Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33
Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps
Xian, M., Yan, B., Song, X., Chen, J., Tang, J., Jiang, Y., Wan, L., Liu, W., Xue, J., Cao, Z., et al. (2025) · Allergy · doi:10.1111/all.16519 · Cited by 37
Tan, R. P., Ryder, I., Yang, N., Lam, Y. T., Santos, M., Michael, P. L., Robinson, D. A., Ng, M. K. C., & Wise, S. G. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.04.008 · Cited by 30
Clinical translation of immunomodulatory therapeutics
Nash, A., Aghlara-Fotovat, S., Hernández, A., Scull, C. M., & Veiseh, O. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113896 · Cited by 32
Baba, S. K., Baba, S. K., Mir, R., Elfaki, I., Algehainy, N. A., Ullah, M. F., Barnawi, J., Altemani, F. H., Alanazi, M. A., Mustafa, S. K., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1164301 · Cited by 36
The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets
Sah, A., & Singewald, N. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108825 · Cited by 46
Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome
Baldwin, A. G., Tapia, V. S., Swanton, T., White, C., Beswick, J. A., Brough, D., & Freeman, S. (2018) · ChemMedChem · doi:10.1002/cmdc.201700731 · Cited by 32
Stevens, N. E., Cowin, A. J., & Kopecki, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01089 · Cited by 31
Psychedelics and Anti-inflammatory Activity in Animal Models
Flanagan, T. W., & Nichols, C. D. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_367 · Cited by 32
Nazari, S., Pourmand, S. M., Motevaseli, E., & Hassanzadeh, G. (2023) · IUBMB Life · doi:10.1002/iub.2759 · Cited by 31
Chronic Inflammation in Obesity and Cancer Cachexia
Divella, R., Gadaleta‐Caldarola, G., & Mazzocca, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082191 · Cited by 36
Dinç, R. (2023) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2023.31.e18 · Cited by 32
The analgesic potential of cytokine neutralization with biologicals
Ebersberger, A. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.040 · Cited by 27
An Injectable Cytokine Trap for Local Treatment of Autoimmune Disease
Zamecnik, C. R., Levy, E. S., Lowe, M. M., Zirak, B., Rosenblum, M. D., & Desai, T. A. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119626 · Cited by 27
Identification of candidate genes associated with triple negative breast cancer
Player, A. N., Abraham, N., Burrell, K., Bengone, I. O., Harris, A., Nunez, L., Willaims, T., Kwende, S. A., & Walls, W. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.147 · Cited by 31
Sharma, D., Arora, S., Banerjee, A., & Singh, J. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102357 · Cited by 36
Redirecting immune signaling with cytokine adaptors
Abhiraman, G. C., Householder, K. D., Rodriguez, G. E., Glassman, C. R., Saxton, R. A., Breuer, C. B., Wilson, S. C., Su, L., Yen, M., Hsu, C. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57681-1 · Cited by 30
Jung, N., Bueb, J., Tolle, F., & Bréchard, S. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.010 · Cited by 25
Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting
Subbarao, S. A. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00796-w · Cited by 25
Karhunen, V., Gill, D., Huang, J. V., Bouras, E., Malik, R., Ponsford, M., Ahola‐Olli, A., Papadopoulou, A., Palaniswamy, S., Sebert, S. P., et al. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000157 · Cited by 26
Molecular targets in bone cancer pain: a systematic review of inflammatory cytokines
Ruivo, J., Tavares, I., & Pozza, D. H. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02464-2 · Cited by 28
Ertveldt, T., Beck, L. D., Ridder, K. D., Locy, H., de Mey, W., Goyvaerts, C., Lecocq, Q., Ceuppens, H., Vlaeminck, Y. D., Awad, R. M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0791 · Cited by 25
In Silico tool for predicting, designing and scanning IL-2 inducing peptides
Mehta, N. K., Lathwal, A., Kumar, R., Kaur, D., & Raghava, G. P. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-08388-2 · Cited by 22
Localized cytokine responses to total knee arthroplasty and total knee revision complications
Prince, N., Penatzer, J. A., Dietz, M. J., & Boyd, J. W. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02510-w · Cited by 23
Hidradenitis suppurativa: A folliculotropic disease of innate immune barrier dysfunction?
Johnston, D. G. W., Kirby, B., & Tobin, D. J. (2021) · Experimental Dermatology · doi:10.1111/exd.14451 · Cited by 23
Novel Analgesics with Peripheral Targets
Ciotu, C. I., & Fischer, M. J. M. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00937-z · Cited by 23
Mehrabadi, A. Z., Shahba, F., Khorramdelazad, H., Aghamohamadi, N., Karimi, M., Bagherzadeh, K., Khoshmirsafa, M., Massoumi, R., & Falak, R. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104200 · Cited by 20
Identification of a Human SOCS1 Polymorphism That Predicts Rheumatoid Arthritis Severity
Lamana, A., Villares, R., Seoane, I. V., Andrés, N., Lucas, P., Emery, P., Vital, E. M. J., Triguero‐Martínez, A., Márquez, A., Ortiz, A. M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01336 · Cited by 22
Díaz-Maroto, N. G., Garcia‐Vicién, G., Polcaro, G., Bañuls, M., Albert, N., Villanueva, A., & Molleví, D. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094960 · Cited by 21
Nawal, R. R., Yadav, S., Duncan, H. F., Talwar, S., Kaushik, A., Singh, V., & Koner, B. C. (2024) · International Endodontic Journal · doi:10.1111/iej.14078 · Cited by 20
Recombinant Spider Silk Bioinks for Continuous Protein Release by Encapsulated Producer Cells
Trossmann, V. T., Heltmann‐Meyer, S., Amouei, H., Wajant, H., Horch, R. E., Steiner, D., & Scheibel, T. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00971 · Cited by 20
Ho, D., Chang, P., Lin, W., Huang, Y., Lin, J.-H., Huang, K.-T., Chan, W.-N., & Cheng, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113953 · Cited by 21
Dinç, R. (2023) · PubMed Central · doi:10.6515/acs.202309_39(5).20230531a · Cited by 26
Variability of cytokine concentration in whole blood serum and bronchoalveolar lavage over time
Valaperti, A., Bezel, P., Eisenring, M., Franzen, D., & Steiner, U. C. (2019) · Cytokine · doi:10.1016/j.cyto.2019.154768 · Cited by 17
Kim, B. H., Park, U. C., Park, S. W., & Yu, H. G. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2021.1872652 · Cited by 16
In silico prediction of phytoconstituents from Ehretia laevis targeting TNF-α in arthritis
Yende, S. R., Shah, S., Arora, S., Moharir, K. S., & Lohiya, G. K. (2021) · Digital Chinese Medicine · doi:10.1016/j.dcmed.2021.09.003 · Cited by 16
Metadata
- Authors
- Rider, P., Carmi, Y., & Cohen, I.
- Affiliations
- Tel Aviv University (IL)
- Western Galilee Hospital (IL)
- Corresponding author
- Cohen, Idan
- Venue
- International Journal of Cell Biology
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-11
- ISSN
- 1687-8876 (ISSN-L)
- 1687-8884
- PMC
- PMC5204077
- OpenAlex
- W2561062294
- Cited by
- 226
- References
- 157
- Citations by year
- 2026: 25 · 2025: 24 · 2024: 13 · 2023: 17 · 2022: 23 · 2021: 39 · 2020: 32 · 2019: 17 · 2018: 27 · 2017: 9
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Cell Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Aliyah and Immigrant Absorption
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- inflammatory cytokines, biologic drugs, anti-TNF antibodies, interleukin-1 receptor antagonist, anti-IL-1 antibodies, anti-IL-6 receptor antibody, cytokine inhibition, autoimmunity, cancer, infection susceptibility, clinical risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.